Shares of generic drugmaker Mylan could rise an additional 20 percent over the next year, as more prescriptions outside of the U.S. are filled by generics.
That's according to a Barron's article which also says the company may also get a boost as drugmakers lose more and more key patents.
If Barron's is right and things are setting up well for Mylan, how should you put money to work in the space?
I have a position in Teva, but with a $150 billion in drugs coming off patents I'd also look at Mylan, counsels Pete Najarian.
In the space I like Dr. Reddy's , adds Tim Seymour.
Got something to to say? Send us an e-mail at firstname.lastname@example.org and your comment might be posted on the Rapid Recap. If you'd prefer to make a comment but not have it published on our website send those e-mails to email@example.com.
CNBC.com with wires